Stocks · News reference
More than 1,600 U.S. cases of cyclosporiasis have been confirmed since May 2026 as infections linked to the foodborne parasite Cyclospora continue to rise nationwideQIAGEN’s FDA-cleared QIAstat-Dx Gastrointestinal Panel
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of
Read original at benzingaQIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hourFDA clearance marks QIAGEN's entry into U.S. bloodstream infection
Read original at benzingaCitigroup analyst Brendan Digan maintains Qiagen (NYSE:QGEN) with a Neutral and raises the price target from $38 to $45.
Read original at benzingaBarclays analyst Luke Sergott maintains Qiagen (NYSE:QGEN) with a Equal-Weight and raises the price target from $38 to $40.
Read original at benzinga